From Small Innovations to Pronounced Medical Breakthroughs
From Small Innovations to Pronounced Medical Breakthroughs

Based in Boston, Genosco is a clinical stage biotech specializing in

the discovery and development of novel kinase inhibitors for

patients with unmet medical needs

Based in Boston, Genosco is a clinical stage

biotech specializing in the discovery and development

of novel kinase inhibitors for patients with unmet

medical needs

  • 01.
    Experienced
    Team

    Dedicated team of experts in
    kinase targeted therapies

  • 02.
    Proprietary
    Discovery
    Platform

    G-SMART™ platform enables us
    to identify rare sequences and
    rapidly generate highly
    selective compounds

  • 03.
    Strong and
    Diverse
    Pipeline

    Multiple independent and
    partnered pipelines

  • 04.
    Proven Track
    Record

    Backed by successful
    out-licensing partnership

  • 01.
    Experienced
    Team

    Dedicated team of experts in
    kinase targeted therapies

  • 02.
    Proprietary
    Discovery
    Platform

    G-SMART™ platform enables us
    to identify rare sequences and
    rapidly generate highly
    selective compounds

  • 03.
    Strong and
    Diverse
    Pipeline

    Multiple independent and
    partnered pipelines

  • 04.
    Proven Track
    Record

    Backed by successful
    out-licensing partnership

G-SMART™ Platform
470+

Mapping / profiling of ATP
binding sites of 470+ human kinases

3,500+

Proprietary chemical
library of 3,500+ master scaffolds

Predictive modelling

to rapidly discover, test and
optimize selective compounds

EGFR
Lazertinib
Development Program
  • Non-Small Cell Lung Cancer (NSCLC)
SYK
SYK Inhibitor (Cevidoplenib)
Development Programs
  • Immune Thrombocytopenia (ITP)
Other Indications
  • Systemic Lupus Erythematosus (SLE)
  • Sjogren’s Syndrome
  • Psoriasis
  • ANCA-associated Vasculitis (AAV)
ROCK2
ROCK2 Inhibitor
Development Program
  • Idiopathic Pulmonary Fibrosis (IPF)
Other Indications
  • Cancer / Immuno-oncology
  • Nonalcoholic Steatohepatitis (NASH)
  • Central Nervous System (CNS)
We are unified under the shared vision to improve patients’ quality of life tomorrow, together.
To achieve this, it is important to focus on strengthening the discovery platform based on cutting-edge science,
and to create an open and positive working environment where employees can unleash their full creativity.
John Koh, CEO of Genosco
Press Release
  • Aug 20, 2024

    Lazertinib With Amivantamab Approved by FDA for Use in NSCLC

  • Dec 22, 2023

    FDA Considers First-Line Amivantamab Plus Lazertinib in EGFR+ NSCLC